XEN implant alone vs phaco-XEN for POAG/PXG: the Stockholm experience

Session Details

Session Title: Glaucoma I

Session Date/Time: Sunday 11/09/2016 | 14:30-16:00

Paper Time: 15:36

Venue: Auditorium C6

First Author: : M.Economou SWEDEN

Co Author(s): :                        

Abstract Details

Purpose:

The Xen implant (Allergan, Dublin, Ireland) is a 6mm porcine gelatin device that is implanted ab interno to the subconjuctival space under direct gonioscopic visualization. The purpose of this study is to compare the safety and efficacy of the Xen implant alone versus Xen in combination with phacoemulsification in patients with medically uncontrolled glaucoma.

Setting:

The study was conducted at a University Eye Hospital which is a referral tertiary center for glaucoma surgery for the whole of Sweden.

Methods:

Retrospectively review of total 30 eyes of 25 patients with POAG or PXG that underwent either implantation of Xen alone or in combination with cataract surgery. Primary outcome measures with one year follow-up included intra-operative and post-operative complications, visual acquity, intraocular pressure (IOP), and number of glaucoma medications.

Results:

10 eyes underwent combined phaco+Xen procedure and 20 eyes received only the Xen. Three patients in the Xen alone group developed early hypotony (IOP<5mmHg) that resolved within a week. Mean preoperative IOP in the combined group was 24.0±7.5mmHg on 2.7±1.3 medications and in the Xen alone group 24.5±6.5mmHg on 2.8±1.2 medications. Mean IOP was reduced to 16.1±4.4mmHg and 1.2±0.8 medications in the combined group and 15.2±4.0mmHg in the Xen alone group at 1-year follow up (p <0.8) on 1.1±0.9 glaucoma medications. Data collection and follow-up are ongoing. The visual acquity has improved only in the combined group.

Conclusions:

In this 1 year safety and feasibility assessment, the safety profile and efficacy data of the Xen implant both in combination with cataract surgery and alone are very promising. Further study with longer-term follow up and a larger number of patients are needed to fully assess the utility of this device.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company